2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Polo-like Kinase (PLK)
  5. Polo-like Kinase (PLK) Activator

Polo-like Kinase (PLK) Activator

Polo-like Kinase (PLK) Isoform Comparison

Polo-like Kinase (PLK) Activator (1):

Cat. No. Product Name Effect Purity
  • HY-W286743
    Nε-(Carboxymethyl)-L-lysine
    		Activator 99.70%
    Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties.